Article Text

Download PDFPDF
Towards improving clinical and patient-centred outcomes in patients with light chain amyloidosis
  1. Kathleen W. Zhang
  1. Department of Internal Medicine, Division of Cardiology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
  1. Correspondence to Dr Kathleen W. Zhang, Department of Internal Medicine, Division of Cardiology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA; kathleen.zhang{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Systemic light chain (AL) amyloidosis is an uncommon disease that results from organ deposition of light chain immunoglobulins produced by a plasma cell neoplasm. Cardiac involvement with the disease is the primary determinant of prognosis, and the cardiac biomarkers N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin have formed the backbone for prognostication in AL amyloidosis over the last decade. Accurate assessment of baseline risk and cardiac treatment response are critical to guide treatment selection and intensity of therapeutic monitoring.

In this issue of Heart, Cohen et al 1 evaluated the 6 min walk test (6MWT) as a prognostic indicator in patients with AL amyloidosis. Seven hundred and ninety-nine patients with newly diagnosed AL amyloidosis seen at the UK National Amyloidosis Centre were prospectively enrolled in an observational study and followed for a median of 32 months. The 6 min walk distance (6MWD) was assessed at baseline and at 6 months, 12 months, 18 months and 24 months following initiation of upfront bortezomib-based therapy; 51 patients also underwent autologous stem cell transplantation. Baseline 6MWD was worse in patients with cardiac involvement and correlated with Mayo disease stage, Eastern Cooperative Oncology Group (ECOG) performance status and New York Heart Association (NYHA) stage. At 6-month and 12-month follow-up, greater improvement in 6MWD was seen in patients with deeper haematological response as well as in patients with cardiac response to therapy by NT-proBNP criteria. Both baseline 6MWD and improvement in …

View Full Text


  • Contributors KZ is the sole contributor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests KZ reports personal fees from Eidos Therapeutics and BridgeBio Pharma, outside of the submitted work.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles

  • Heart failure and cardiomyopathies
    Oliver C Cohen Ananth Sathyanath Aviva Petrie Sriram Ravichandran Steven Law Richa Manwani Darren Foard Sajitha Sachchithanantham Shameem Mahmood Ana Martinez-Naharro Marianna Fontana Carol J Whelan Philip N Hawkins Helen J Lachmann Julian D Gillmore Ashutosh D Wechalekar